Olanzapine SPE2D2-25-D-0011 Award
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
DLA TROOP SUPPORT
Contract Value
Not provided
Codes & Classification
Solicitation Number
SPE2D2-25-D-0011
NAICS
325412 - Pharmaceutical Preparation Manufacturing
Classification Code
6505
Additional Details
Documents3
The Defense Logistics Agency (DLA) Troop Support has issued an award notice for contract SPE2D2-25-D-0011, pertaining to the supply of Olanzapine Tablets. This procurement falls under the North American Industry Classification System (NAICS) code 325412, which covers Pharmaceutical Preparation Manufacturing, and is further classified under Product Service Code (PSC) 6505, indicating drugs and biologicals.
The primary objective of this contract is to secure a reliable supply of Olanzapine Tablets, a pharmaceutical product commonly used in the treatment of certain mental/mood conditions. The scope of the award encompasses the manufacturing and delivery of these tablets, ensuring that the U.S. government maintains access to essential medications for its operational needs. The place of performance for this contract is specified as Toronto, Ontario, Canada, indicating that the manufacturing or distribution activities will be conducted from this location.
DLA Troop Support, a federal office responsible for providing worldwide logistics support to the military services, is the contracting entity for this award. The agency’s focus on pharmaceutical preparation underscores the critical nature of this procurement in supporting the health and readiness of military personnel.
Key requirements for this contract include compliance with all applicable pharmaceutical manufacturing standards and regulations, as well as the ability to deliver Olanzapine Tablets in accordance with the government’s specifications and timelines. Contractors are expected to demonstrate robust quality assurance processes and a proven track record in pharmaceutical production.
The notice is currently active and was posted on April 23, 2025. Interested parties seeking further information or clarification may contact the primary point of contact, Joshua Tankel, at [email protected] or 215-737-2745, or the secondary contact, Jason Wray, at [email protected] or 215-737-0614.
This award notice is published on SAM.gov, with additional details and attachments available via the provided opportunity link. Contractors with capabilities in pharmaceutical manufacturing, particularly those with experience in supplying government or defense agencies, may find this opportunity aligns with their expertise and operational strengths. No set-aside requirements or special considerations are specified in the notice.
Overall, this contract represents a significant opportunity for qualified pharmaceutical manufacturers to support the U.S. government’s mission by ensuring the availability of critical medications.